HOUSE BILL REPORT
This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent.
As Reported by House Committee On:
Health Care & Wellness
Title: An act relating to the prescribing of schedule II controlled substances.
Brief Description: Allowing the prescription of a schedule II controlled substance to treat a binge eating disorder.
Sponsors: Senate Committee on Health Care (originally sponsored by Senators Rivers, Keiser, Cleveland, Miloscia and Chase).
Health Care & Wellness: 2/24/16, 2/26/16 [DPA].
HOUSE COMMITTEE ON HEALTH CARE & WELLNESS
Majority Report: Do pass as amended. Signed by 15 members: Representatives Cody, Chair; Riccelli, Vice Chair; Schmick, Ranking Minority Member; Harris, Assistant Ranking Minority Member; Caldier, Clibborn, DeBolt, Jinkins, Johnson, Moeller, Robinson, Rodne, Short, Tharinger and Van De Wege.
Staff: Jim Morishima (786-7191).
Authorized prescribers of controlled substances may only prescribe schedule II amphetamines or schedule II non-narcotic stimulants for certain diseases or conditions or under certain circumstances, including for the:
treatment of narcolepsy;
treatment of hyperkinesis;
treatment of drug-induced brain dysfunction;
treatment of epilepsy;
differential diagnosis of depression;
treatment of depression that is refractory to other therapeutic modalities;
treatment of multiple sclerosis; or
clinical investigation of the effects of the drugs.
Summary of Amended Bill:
Authorized prescribers of controlled substances may prescribe schedule II amphetamines or schedule II non-narcotic stimulants for any disease states or conditions for which the United States Food and Drug Administration (FDA) has approved an indication.
Amended Bill Compared to Substitute Bill:
The amended bill removes the specific authorization for schedule II amphetamines and non-narcotic stimulants to be prescribed for binge eating disorder. Instead, the amended bill authorizes prescriptions for such drugs for any disease states or conditions for which the FDA has approved an indication.
Fiscal Note: Available.
Effective Date of Amended Bill: The bill takes effect 90 days after adjournment of the session in which the bill is passed.
Staff Summary of Public Testimony:
(In support) Binge eating disorder affects both men and women. The FDA recently approved a schedule II amphetamine for the treatment of the condition, but providers are currently unable to prescribe it. The decision on what medication should be prescribed should be between the patient and the provider. The full level of medications should be available to patients. A complete psychiatric formulary should be issued by the Pharmacy Quality Assurance Commission—this bill is a step in the right direction. This bill allows providers to treat people who need treatment.
Persons Testifying: Jeff Gombosky, Shire U.S. Inc.; Seth Dawson, National Alliance on Mental Illness; and BJ Cavnor, One in Four Chronic Health.
Persons Signed In To Testify But Not Testifying: None.